The journey of the Mayflower in 1620 is a cornerstone of early American history, but beyond the collective tale of survival and settlement lies a tapestry of personal stories, tragedies, and triumphs.
MSN: The dark secrets of the Mayflower passengers that history classes rarely mention or explain
The dark secrets of the Mayflower passengers that history classes rarely mention or explain
MarketWatch: ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA(R) Plus CAR-NK, Chemo-Free Therapy
The MarketWatch News Department was not involved in the creation of this content. -- Primary endpoint of QUILT-3.078 is overall survival; median overall survival has not yet been reached, with 19 of ...
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA(R) Plus CAR-NK, Chemo-Free Therapy
The American Journal of Managed Care: Drug Survival of Psoriasis Biologics Associated With Efficacy, Safety Profile
Drug survival rates of biologics in patients with psoriasis were shown to be associated with their effectiveness and safety profiles, in which incidence of psoriatic arthritis, nail involvement, and ...
ascopubs.org: Gene Expression Profile Predicts Patient Survival of Gastric Cancer After Surgical Resection
Data of cDNA microarrays were obtained from 18 pairs of cancerous and noncancerous gastric tissues. Nine patients who survived > 30 months were identified as good survival, and the other nine, who ...
Gene Expression Profile Predicts Patient Survival of Gastric Cancer After Surgical Resection
Dr. Miranda Gogishvili, a medical oncologist at the High Technology Medical Center, University Clinic in Tbilisi, Georgia, said the six-year follow-up showed a median overall survival of 26 months ...
The New England Journal of Medicine: Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer
ascopubs.org: Plasma cytokine profiles and survival outcomes in the 1801 phase 1/2 clinical trial of 9-ING-41 (elraglusib) in patients with advanced cancer.
Plasma cytokine profiles and survival outcomes in the 1801 phase 1/2 clinical trial of 9-ING-41 (elraglusib) in patients with advanced cancer.
MedPage Today: Recurrent Metastatic NSCLC vs De Novo Stage IV: How Do Survival Rates Compare?
Recurrent Metastatic NSCLC vs De Novo Stage IV: How Do Survival Rates Compare?
Business Wire: ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
When the ship Mayflower set sail from England for the New World in 1620, it brought with it 102 passengers and a crew of about 30 collectively known as the Pilgrims. Shortly afterward, the Plymouth ...